Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 2;7(5):e882.
doi: 10.1097/HS9.0000000000000882. eCollection 2023 May.

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Kai Wille  1 , Maja Brouka  1 , Johannes Bernhardt  1 , Axel Rüfer  2 , Emilia Niculescu-Mizil  3 , Mirjana Gotic  4 , Susanne Isfort  5   6 , Steffen Koschmieder  5   6 , Tiziano Barbui  7 , Parvis Sadjadian  1 , Tatjana Becker  1 , Vera Kolatzki  1 , Raphael Meixner  8 , Hannah Marchi  8   9 , Christiane Fuchs  8   9 , Frank Stegelmann  10 , Konstanze Döhner  10 , Jean-Jacques Kiladjian  11 , Martin Griesshammer  1
Affiliations

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET

Kai Wille et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

KW and MG declares funding, advisory board honoraria and other financial support (eg, travel support) from Amgen, AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, Janssen, Gilead, AstraZeneca, Lilly. SI declares honoraria from Pfizer, AOP Orphan, Novartis, Incyte and Abbvie, advisory board honoraria from Pfizer, Novartis, GSK and Incyte and other financial support (travel support) from Pfizer, Novartis, AOP Orphan and Alexion. SK reports funding from Novartis, Bristol-Myers Squibb, Janssen/Geron; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, and GSK; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, Sierra Oncology, Karthos, Imago Bioscience, and GSK; serves as an editor for HemaSphere; and other financial support (eg, travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Biosciences, and GSK. KD declares consulting/advisory role/honoraria from AbbVie, Celgene/BMS, Novartis, CTI BioPharma Corp, and Roche. J-JK declares consulting/advisory role/honoraria from AbbVie, BMS, Novartis, AOP Health. All the other authors have no conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Graphical representation of the application of GLMMs of the 129 PV pregnancies in relation to the outcome of the OR (95% CI ). Administration of ASA/LMWH (P = 0.001) and IFN (P = 0.023) was statistically significantly associated with a lower risk of miscarriage than standard antenatal care. ASA = acetylsalicylic acid; CI = confidence interval; IFN = interferon; LMWH = low molecular weight heparin; PV = polycythemia vera; OR = odds ratio; GLMMs = generalized linear mixed models.
Figure 2.
Figure 2.
Graphical representation of GLMMs of the 129 PV pregnancies in terms of maternal complications. No significant association was found between these variables and maternal complications. CI = confidence interval; GLMMs = generalized linear mixed models; PV = polycythemia vera.
See this image and copyright information in PMC

References

    1. Moulard O, Mehta J, Fryzek J, et al. . Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–297. - PubMed
    1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94:133–143. - PubMed
    1. Robinson S, Bewley S, Hunt BJ, et al. . The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica. 2005;90:1477–1483. - PubMed
    1. Maze D, Kazi S, Gupta V, et al. . Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2:e1912666–e1912666. - PMC - PubMed
    1. Bertozzi I, Rumi E, Cavalloni C, et al. . Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. Am J Hematol. 2018;93:E234–E235. - PubMed